DE69515038D1 - Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen - Google Patents

Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen

Info

Publication number
DE69515038D1
DE69515038D1 DE69515038T DE69515038T DE69515038D1 DE 69515038 D1 DE69515038 D1 DE 69515038D1 DE 69515038 T DE69515038 T DE 69515038T DE 69515038 T DE69515038 T DE 69515038T DE 69515038 D1 DE69515038 D1 DE 69515038D1
Authority
DE
Germany
Prior art keywords
raloxifen
analogs
producing
viral diseases
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69515038T
Other languages
English (en)
Other versions
DE69515038T2 (de
Inventor
Andrew Lawrence Glasebrook
David Lynn Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69515038D1 publication Critical patent/DE69515038D1/de
Application granted granted Critical
Publication of DE69515038T2 publication Critical patent/DE69515038T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
DE69515038T 1994-08-22 1995-08-21 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen Expired - Fee Related DE69515038T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/294,171 US5494920A (en) 1994-08-22 1994-08-22 Methods of inhibiting viral replication
PCT/US1995/010580 WO1996005830A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting viral replication

Publications (2)

Publication Number Publication Date
DE69515038D1 true DE69515038D1 (de) 2000-03-16
DE69515038T2 DE69515038T2 (de) 2000-06-29

Family

ID=23132219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69515038T Expired - Fee Related DE69515038T2 (de) 1994-08-22 1995-08-21 Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen

Country Status (15)

Country Link
US (1) US5494920A (de)
EP (1) EP0771200B1 (de)
JP (1) JPH10504572A (de)
AT (1) ATE189601T1 (de)
AU (1) AU3408795A (de)
CA (1) CA2198122A1 (de)
DE (1) DE69515038T2 (de)
DK (1) DK0771200T3 (de)
ES (1) ES2141957T3 (de)
GR (1) GR3033269T3 (de)
IL (1) IL115014A0 (de)
MX (1) MX9701329A (de)
PT (1) PT771200E (de)
WO (1) WO1996005830A1 (de)
ZA (1) ZA956986B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3798024B2 (ja) 1995-12-13 2006-07-19 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進物質レセプターアッセイ
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
ME00074B (me) * 1996-03-26 2010-10-10 Lilly Co Eli Benzotiofeni, formulacije koje ih sadrže i proizvod
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2010048415A1 (en) * 2008-10-22 2010-04-29 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
CA3204588A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
CN105246501B (zh) 2013-03-27 2021-01-12 雪松-西奈医学中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
ATE189601T1 (de) 2000-02-15
EP0771200A4 (de) 1997-09-10
ES2141957T3 (es) 2000-04-01
CA2198122A1 (en) 1996-02-29
ZA956986B (en) 1997-02-21
IL115014A0 (en) 1995-12-08
GR3033269T3 (en) 2000-09-29
EP0771200A1 (de) 1997-05-07
EP0771200B1 (de) 2000-02-09
AU3408795A (en) 1996-03-14
WO1996005830A1 (en) 1996-02-29
DE69515038T2 (de) 2000-06-29
US5494920A (en) 1996-02-27
DK0771200T3 (da) 2000-05-15
PT771200E (pt) 2000-07-31
MX9701329A (es) 1997-05-31
JPH10504572A (ja) 1998-05-06

Similar Documents

Publication Publication Date Title
DE69515038T2 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
DE69428325T2 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
ATE173252T1 (de) Arylmorpholine, herstellung und verwendung
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
ATE240101T1 (de) Verwendung von 2-phenyl-3- aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
ATE179890T1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee